References
- Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743.
- Schmitt J, Bauer A, Meurer M. Atopic eczema in adulthood. Hautarzt. 2008;59(10):841–850.
- Paller AS, McAlister RO, Doyle JJ, et al. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr. 2002;41(5):323–332.
- Koblenzer CS, Koblenzer PJ. Chronic intractable atopic eczema: its occurrence as a physical sign of impaired parent–child relationships and psychologic developmental arrest: improvement through parent insight and education. Arch Dermatol. 1988;124(11):1673–1677.
- Silverberg JI, Garg NK, Paller AS, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56–66.
- Řeháková T, Stepanov A, Jirásková N. Steroid-induced glaucoma as a complication of atopic eczema local treatment. Cesk Slov Oftalmol. 2017;73(2):64–68.
- Celakovská J, Bukač J. SCORAD reflects the duration of atopic dermatitis lesions. Indian J Dermatol. 2013;58(3):247.
- Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407.
- Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents. Exp Dermatol. 2018;27(1):22–29.
- O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl. 2):ii111–ii115.
- Brumfiel CM, Patel MH, Severson KJ, et al. Ruxolitinib cream in the treatment of cutaneous lichen planus: a prospective, open-label study. J Invest Dermatol. 2022;142:2109–2116.e4.
- Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82(6):1305–1313.
- Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572–582.
- Naeimifar A, Ahmad Nasrollahi S, Akbari Javar H, et al. Designing a topical nanoliposomal formulation of ruxolitinib phosphate. Pharm Sci. 2022.
- Alves de Medeiros K, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLOS One. 2016;11(10):e0164080.
- Gerson S, Caimi P, Basem M, et al. Chapter 57 – pharmacology and molecular mechanisms of antineoplastic agents for hematologic malignancies. In: Hoffman R, Benz EJ, Silberstein LE, et al., editors. Hematology. 7th ed. Elsevier; 2018. p. 849–912.
- Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci. 2008;34(4–5):203–222.
- Yazdanparast T, Yazdani K, Humbert P, et al. Biophysical measurements and ultrasonographic findings in chronic dermatitis in comparison with uninvolved skin. Indian J Dermatol. 2019;64(2):90–96.
- Nasrollahi SA, Hassanzade H, Moradi A, et al. Safety assessment of tretinoin loaded nano emulsion and nanostructured lipid carriers: a non-invasive trial on human volunteers. Curr Drug Deliv. 2017;14(4):575–580.
- Jenning V, Gysler A, Schafer-Koring M, et al. Vitamin a loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2000;49(3):211–218.
- Van Zuuren EJ, Fedorowicz Z, Arents BWM. Emollients and moisturisers for eczema: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol. 2017;177(5):1256–1271.
- Australasian Society of Clinical Immunology and Allergy [webpage on the Internet]. Atopic dermatitis (eczema). Brookvale, Australia: Australasian Society of Clinical Immunology and Allergy; 2016 [cited 2016 Jan 29]. Available from: https://www.allergy.org.au/images/pcc/
- Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818–823.
- Al-Adawiyah R, Putera AM, Astri L, et al. Determinant factors of recurrence atopic dermatitis symptoms in children: a cross-sectional study. Ann Med Surg. 2021;70:102847.